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Abstract
The serine protease inhibitor, plasminogen activator inhibitor Type-1 (PAI-1) is
a metastable protein that undergoes an unusual transition to an inactive conformation with a short half-life of only 1–2 hr. Circulating PAI-1 is bound to a
cofactor vitronectin, which stabilizes PAI-1 by slowing this latency conversion.
A well-characterized PAI-1-binding site on vitronectin is located within the
somatomedin B (SMB) domain, corresponding to the first 44 residues of the protein. Another PAI-1 recognition site has been identified with an engineered form
of vitronectin lacking the SMB domain, yet retaining PAI-1 binding capacity
(Schar, Blouse, Minor, Peterson. J Biol Chem. 2008;283:28487–28496). This additional binding site is hypothesized to lie within an intrinsically disordered
domain (IDD) of vitronectin. To localize the putative binding site, we constructed a truncated form of vitronectin containing 71 amino acids from the Nterminus, including the SMB domain and an additional 24 amino acids from the
IDD region. This portion of the IDD is rich in acidic amino acids, which are
hypothesized to be complementary to several basic residues identified within an
extensive vitronectin-binding site mapped on PAI-1 (Schar, Jensen, Christensen,
Blouse, Andreasen, Peterson. J Biol Chem. 2008;283:10297–10309). Steady-state
and stopped-flow fluorescence measurements demonstrate that the truncated
form of vitronectin exhibits the same rapid biphasic association as full-length
vitronectin and that the IDD hosts the elusive second PAI-1 binding site that lies
external to the SMB domain of vitronectin.
KEYWORDS
fluorescence, intrinsic disorder, PAI-1, stopped-flow kinetics, vitronectin

Abbreviations: DTT, dithiothreitol; IANBD, (NBD) ethylenediamine; IDD, intrinsically disordered domain; IMAC, immobilized metal affinity
chromatography; kassoc, second-order association rate constant for complex formation; MALDI-TOF-MS, matrix-assisted laser desorption/ionization
time of flight mass spectrometry; NBD, N,N0 -dimethyl-N-acetyl-N0 -methyl(7-nitrobenz-2-oxa-1,3-diazol-4-yl)ethylenediamine; PAI-1, plasminogen
activator inhibitor type-1; RCL, reactive center loop; SANS, small-angle neutron scattering; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel
electrophoresis; SMB, somatomedin B domain; SMB–IDD, 130 amino acids from the N-terminus of vitronectin that contains the somatomedin B
domain and the intrinsically disordered domain; SMB–IDDΔ71, 71 amino acids from the N-terminus of vitronectin that contains the SMB domain
and a portion of the intrinsically disordered domain; tPA, tissue-type plasminogen activator; uPA, urokinase plasminogen activator; uPAR, urokinasetype plasminogen activator receptor; VMD, Visual Molecular Dynamics.
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1 | INTRODUCTION
Plasminogen activator inhibitor Type-1 (PAI-1) is an
important regulator of hemostasis, serving as the primary
inhibitor for both tissue-type plasminogen activator (tPA)
and urokinase-type plasminogen activator (uPA).1–4 PAI-1
is produced by a wide variety of cells.5–12 While it is primarily stored in platelets, it also is found throughout the
circulation and in the extracellular matrix. The increased
expression of PAI-1 in vivo suppresses fibrinolysis, consequently leading to pathological fibrin deposition and tissue damage.12,13 Elevated PAI-1 levels are associated with
cardiovascular diseases and cancer progression, as well
as inflammatory diseases such as obesity and the metabolic syndrome.14–22 PAI-1 is a member of the serpin
superfamily,23–25 adopting the canonical fold characterized
by three β-sheets, and several α-helices packed mostly on
one side of the major central β-sheet (Figure 1). The key to
the inhibitory function of PAI-1 is an exposed loop, the
reactive center loop (RCL), which contains a cleavage site
recognized by the target proteases. Upon attack of the proteases on the RCL, an acyl-intermediate forms, followed by
a large conformational change wherein the protease is
translocated to the distal end of the serpin. The covalent
complex between the serpin and protease is stable and
long-lived, resulting in inactivation of the target protease.
A unique characteristic of PAI-1 is its conformational
flexibility. Active PAI-1 is relatively unstable under physiological conditions and readily converts to an inactive,
latent form via a large conformational change that occurs
upon insertion of the RCL into the protein core where it is
incorporated into the central β-sheet. The half-life for this
latency transition is 1–2 hr.27–30 Various factors affect the
rate of this latency transition, including temperature, pH,
ionic strength, metal, and cofactor binding.29,31–34 Circulating PAI-1 exists in a tight complex with an important
cofactor, the plasma glycoprotein vitronectin.33,35 Binding
to vitronectin stabilizes PAI-1 by decreasing the rate of the
latency transition; vitronectin also localizes PAI-1 to the
surface of blood clots where it effectively modulates fibrinolysis36 and to tissues where it has roles in protease inhibition as well as non-protease-dependent functions.37–41
PAI-1 and vitronectin are found together in the extracellular matrix in a variety of disease pathologies, including
tumor development, angiogenesis, inflammation, and
necrosis.42–44
In addition to binding to PAI-1, vitronectin associates
with an assortment of biomolecules, including heparin,
PAI-1, integrins, and the urokinase receptor (uPAR) and
provides a regulatory link between cell adhesion and
physiological proteolysis.40,45 While the structure of fulllength vitronectin has proven refractory, computational
approaches combined with X-ray crystallography, NMR,
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and small-angle X-ray scattering, have provided a model
for a domain organization.46–49 A small 44 amino acid
domain at the N-terminus of vitronectin, called the
somatomedin B (SMB) domain, is the best-characterized
region of the protein.46,50 It contains the binding sites for
PAI-1 and uPAR,51–53 immediately flanked by an RGD
motif (residues 45–47) that binds integrins and promotes
cell adhesion, spreading, and migration.54,55 PAI-1 binding to the SMB domain can block and regulate the binding of integrins and uPAR.40,56 The region encompassing
amino acids ~50–130 is an unstructured linker between
the SMB domain and central domain of vitronectin.49

F I G U R E 1 Structural model of the PAI-1:SMB complex
highlighting the engineered residues used in this work (PDB code:
1OC0). PAI-1 and SMB are represented with cartoon structures and
colored in silver and red, respectively. Sites corresponding to the
PAI-1 residues in the flexible-joint region that are involved in the
interaction with the SMB from vitronectin, including Arg-101, Met112, and Gln-125, are colored in green. Sites corresponding to PAI-1
residues involved in the more extensive interaction with vitronectin
outside the SMB domain, including Lys-71, Arg-78, Tyr-81, Lys-82,
Arg-117, and Arg-120, are colored in cyan. All figures are generated
in Visual Molecular Dynamics (VMD)26 Left: Three-dimensional
representation of the PAI-1:SMB complex. This figure illustrates the
canonical features of the serpin structure, with a reactive center
loop (RCL; added in as a blue dashed line) that reacts with the
protease and a prominent central β-sheet surrounded by helices
and loop structures. The SMB domain is a compact structure held
together by four disulfide bonds that interacts at the “base” of the
PAI-1 molecule in the flexible-joint region (α-helixes hE, hF, and
β-sheet s1A). The residues changed via site-directed mutagenesis,
Phe-116 and Ser-121, are shown as spheres and are colored in gold
and purple, respectively. Right: Zoomed-in representation of the PAI1:SMB complex. This view shows details of the two vitronectinbinding sites identified in PAI-1, with the engineered residues
shown in ball and stick models. Phe-116 is gold and Ser-121 is
purple. PAI-1, plasminogen activator inhibitor type-1; SMB,
somatomedin B
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This central domain and the C-terminal domain are
predicted to house β-propeller structures and are known
to contain binding sites for heparin.49 Our initial computational analysis of the vitronectin domain structure
suggested that the ~80 amino acid linker between the
SMB and central domains is prone to disorder,49 and further studies have demonstrated that this region has hallmark features of an intrinsically disordered domain
(IDD).47,57 We have sustained interest in this region and
its role in the functional properties of vitronectin.
The interaction between vitronectin and PAI-1 has been
widely investigated.36,39,51 When PAI-1 binds to vitronectin,
a permanent conformational change in vitronectin ensues,
which leads to the generation of vitronectin oligomers.58
Moreover, binding of PAI-1 to vitronectin leads to an intermediate with an unusual stoichiometry of 2:1 (PAI-1:
vitronectin), which promotes assembly into higher-order
PAI-1:vitronectin complexes.59 X-ray crystallography has
revealed important details regarding the binding of PAI-1
to the SMB domain of vitronectin.46 Residues involved in
binding to the SMB domain come from the “flexible joint”
region of PAI-1 (α-helixes hE, hF, and β-sheet s1A)46 (see
Figure 1). The binding of the SMB domain at this site
restricts the dynamics of PAI-1 at the base of the central
β-sheet60 and constrains its ability to accommodate insertion of the RCL by restricting the expansion of this
β-sheet. In this manner, SMB binding stabilizes PAI-1 in
its active conformation and opposes the conversion to the
inactive, latent form that contains an additional strand
inserted into the central β-sheet.46 A single-turn α-helix
within the SMB domain hosts the main interaction site
on vitronectin that is complementary to the flexible-joint
region of PAI-1.46
Although prior structural work on the PAI-1:SMB complex provided keen insights into the mechanism of PAI-1
stabilization by vitronectin, the picture remains incomplete
regarding the concomitant changes in vitronectin and
assembly of higher-order oligomers. It should be noted that
the PAI-1:SMB complex is a stable 1:1 complex with an
SMB structure that is largely unperturbed compared to the
structure of SMB alone. Thus, the structural changes that
are induced in vitronectin upon PAI-1 binding, and that
lead to association into oligomeric forms, must occur outside of the SMB domain.
The location of an additional PAI-1 binding site
within vitronectin has been hotly debated over the
years.36,57,58,61–66 The picture that has emerged from mutagenesis and kinetic studies shows that PAI-1 and
vitronectin interact over extensive binding surfaces.58,61,62
A binding site located outside the SMB domain of
vitronectin was demonstrated by engineering a vitronectin
variant lacking the SMB domain and showing that it still
bound to PAI-1, albeit with a lower affinity.62 Unlike the
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SMB domain, this vitronectin variant lacking the SMB
domain binds to both active and latent PAI-1 and does not
stabilize active PAI-1. Several PAI-1 residues, including
Arg-117 and Arg-120 on hE and Lys-71, Arg-78, Tyr-81,
Lys-82 on hD, were identified as components of a binding
site for vitronectin outside of the SMB domain.61 Furthermore, a study using stopped-flow fluorescence with an
IANBD (N,N0 -dimethyl-N-acetyl-N0 -methyl (7-nitrobenz2-oxa-1,3-diazol-4-yl)ethylenediamine)-labeled PAI-1 interacting with vitronectin or the SMB domain also indicated
that PAI-1 binding to vitronectin is a two-step process versus one-step binding to the isolated SMB domain.58
While some details have been uncovered regarding the
composition of the more extensive binding site in PAI-1,
the identity of the complementary binding site on
vitronectin is still unknown. The close proximity of the primary SMB-binding site and the additional vitronectinbinding site on PAI-1 suggests that dual binding regions
within vitronectin may also be located close to one another.
This observation has prompted evaluation of the IDD
linker region as a potential locus housing the more extensive binding site within vitronectin. Previous studies have
shown that IDD regions in several proteins can adopt more
organized structures upon ligand binding, resulting in
altered functions.67–69 Intrinsically disordered proteins have
noted roles in neural development, cell signaling, synaptic
transmission, and cell cycle regulation.70,71 In some
instances, the same intrinsically disordered sequence can
adopt different structures, depending on the binding partner, exhibiting a versatility that was unrecognized in protein structure for many years.72
We have recently investigated the role of the vitronectin
IDD with regards to PAI-1 binding by utilizing small-angle
neutron scattering (SANS) approaches, which indicated
that the IDD gains structure and becomes more compact
upon PAI-1 binding.57 The highly positively charged nature
of residues in PAI-1 that comprise the more extensive binding site61 suggests that the complementary binding site on
vitronectin may include several negatively charged residues.
Recognizing the density of negatively charged residues
within the linker as one hallmark feature of IDD regions,
we hypothesized that residues in this unstructured linker
region of vitronectin comprise the PAI-1 binding site that
exists external to the SMB domain. To test this idea, we
constructed a truncated form of vitronectin corresponding
to the first 71 amino acids (denoted SMB–IDDΔ71 and
comprising the SMB domain and a portion of the IDD
linker region). Within the IDD region, the sequence
“VFTMPEDEYTVYDDGEEKNNATVH” contains many
negatively charged residues (in bold), including Glu-53,
Asp-54, Glu-55, Asp-60, Asp-61, Glu63, and Glu-64. Steadystate and stopped-flow fluorescence approaches were utilized to study the binding of PAI-1 with several vitronectin
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variants, including the isolated SMB domain, a 130 amino
acid variant harboring the SMB and IDD regions (SMB–
IDD),57 and the truncated SMB–IDDΔ71 form. This work
demonstrates that the SMB–IDDΔ71 protein exhibits similar binding properties with the SMB–IDD and full-length
vitronectin, thus localizing the additional PAI-1-binding site
to the highly charged region spanning residues 48–71
in vitronectin.

2 | R E SUL T S
2.1 | Localizing a binding site using
intrinsic tryptophan fluorescence to
monitor binding of PAI-1(-4W) + F116W to
SMB, SMB–IDD, or SMB–IDDΔ71
Because the fluorescence of tryptophan is readily measured, with spectral properties that are sensitive to the
polarity of the local environment, this amino acid provides a convenient intrinsic probe that has been useful in
many studies to measure conformational changes and
ligand binding. Native PAI-1 contains four tryptophan
residues which are spaced throughout the molecule; the
fluorescence properties of the four tryptophans and their
contributions to functional stability have been characterized.73,74 In previous work, we generated a fluorescently
silent version of PAI-1 by incorporating 4-fluorotryptophan to replace tryptophan during biosynthesis of
PAI-1.73 For this study, we have achieved a similar goal
with the synthesis of PAI-1 with all four tryptophans replaced with phenylalanines. This “tryptophan-null” PAI-1
(PAI-1(-4W)) provides an opportunity to introduce a single tryptophan as a fluorescence reporter group at any
given site of interest in the sequence. Here our goal was
to engineer a PAI-1 protein with the single tryptophan
reporter located within the more extensive vitronectinbinding site that is separate from the flexible-joint
region.61 We identified Phe-116 in close proximity to two
residues (Arg-117, Arg-120) identified within the more
extensive binding site on PAI-1 (Figure 1) and used sitedirected mutagenesis to convert this residue to a tryptophan to generate PAI-1(-4W) + F116W and study the
interactions between PAI-1 and vitronectin outside the
SMB region.
The tryptophan fluorescence emission spectrum of PAI-1
(-4W) + F116W in the absence or presence of SMB, SMB–
IDD, or SMB–IDDΔ71 was measured at steady-state, saturating conditions (Figure 2). The binding of PAI-1(-4W)
+ F116W with SMB–IDD or SMB–IDDΔ71 results in a
~7% enhancement of fluorescence intensity with a blue shift
in the emission peak from 351 to 341 nm. This fluorescence
change indicates that the tryptophan at position 116 is

F I G U R E 2 Steady-state fluorescence spectra of PAI-1(-4W)
+ F116W in the absence or presence of truncated vitronectin
variants. Spectra were measured using a PAI-1(-4W) + F116W
concentration of 300 nM. The engineered vitronectin proteins were
added in a final concentration of 1.2 μM. PAI-1(-4W) ± F116W alone:
black trace; PAI-1(-4W) ± F116W with SMB: gray trace; PAI-1(-4W)
± F116W with SMB–IDDΔ71: gray dashed trace; PAI-1(-4W)
± F116W with SMB–IDD: black dotted trace. IDD, intrinsically
disordered domain; PAI-1, plasminogen activator inhibitor type-1

transferred to a more hydrophobic environment upon binding to the vitronectin fragments (SMB–IDD or SMB–
IDDΔ71). In contrast, binding of the isolated SMB domain
to PAI-1(-4W) + F116W gives no change in the amplitude
of the fluorescence measured, although a small blue shift
in the peak maximum is apparent, indicating limited or no
burial of surface area in the region of tryptophan-116 upon
binding to the SMB. It is noteworthy that the binding of
SMB–IDD and SMB–IDDΔ71 to PAI-1(-4W) + F116W give
nearly indistinguishable changes in fluorescence, demonstrating that the PAI-1-binding site located within the IDD
is localized to the “VFTMPEDEYTVYDDGEEKNNATVH”
sequence.

2.2 | Differences in PAI-1121-NBD binding
to SMB, relative to SMB–IDD and SMB–
IDDΔ71, are apparent in stopped-flow
fluorescence experiments
The interesting similarities in the binding of SMB–IDD
and SMB–IDDΔ71 to PAI-1(-4W) + F116W, and stark
contrast with SMB–IDD alone, prompted us to more
carefully evaluate the kinetics of binding to determine if
the dual binding sites in the SMB and IDD regions were
sufficient to account for the biphasic binding previously
observed with full-length vitronectin and PAI-1.58 This
was apparent from some of our first work that established
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F I G U R E 3 Fluorescence measurements on PAI-1121-NBD alone or complexed with truncated vitronectin variants. (a) Steady-state
fluorescence spectra of PAI-1121-NBD (50 nM) with the absence or presence of vitronectin variants (200 nM). PAI-1121-NBD alone: black trace;
PAI-1121-NBD with SMB: gray trace; PAI-1121-NBD with SMB–IDDΔ71: gray dashed trace; PAI-1121-NBD with SMB–IDD: black dotted trace.
(b) Titration of PAI-1121-NBD with engineered vitronectin variants. The fluorescence intensity of PAI-1121-NBD (50 nM) was measured using an
excitation wavelength of 480 nm and an emission wavelength of 530 nm, with addition of varying concentrations (from 0.625 to 800 nM) of
engineered vitronectin fragments. PAI-1121-NBD with SMB: gray trace; PAI-1121-NBD with SMB–IDDΔ71: black trace. IDD, intrinsically
disordered domain; PAI-1, plasminogen activator inhibitor type-1; SMB, somatomedin B

F I G U R E 4 Stopped-flow fluorescence progress curves of PAI1121-NBD (50 nM) mixing with truncated vitronectin variants
(200 nM). PAI-1121-NBD with SMB: black trace; PAI-1121-NBD with
SMB–IDDΔ71: gray trace; PAI-1121-NBD with SMB–IDD: dark gray
trace. IDD, intrinsically disordered domain; PAI-1, plasminogen
activator inhibitor type-1; SMB, somatomedin B

an additional binding site that extended beyond the SMB
domain, utilizing rapid-reaction kinetics to contrast the
binding of the isolated SMB domain and intact
vitronectin.58 In order to study the presteady-state kinetics
of the reaction between PAI-1 and the various truncated
vitronectin species in this study, we utilized a published
approach with a fluorescent label on Ser-121 of PAI-1,58
another residue in close proximity to Arg-117 and Arg-120.
Thus, Ser-121 (Figure 1), was changed to Cys and labeled
with the environmentally responsive fluorophore, IANBD,
which gave us more sensitivity than the F116W probe to

measure binding. The steady-state fluorescence spectra of
PAI-1121-NBD alone or with saturating concentrations of
SMB, SMB–IDD, or SMB–IDDΔ71 are shown in
Figure 3a. PAI-1121-NBD binding to SMB–IDD or SMB–
IDDΔ71 exhibits almost identical spectra, with a 57% intensity increase at the peak wavelength and a blue shift from
541 to 535 nm, whereas PAI-1121-NBD binding to SMB
results in a much smaller intensity increase of 27%. The differences between PAI-1121-NBD binding to SMB–IDD and
SMB–IDDΔ71 versus SMB are consistent with PAI-1(-4W)
+ F116W fluorescence results, that is, the interaction
between PAI-1 with SMB–IDD or SMB–IDDΔ71 at the proposed second binding site transfers the fluorophores into a
more hydrophobic environment and causes an intensity
increase and blue shift of the emitted fluorescence.
The substantial increase in fluorescence upon binding of
PAI-1121-NBD was exploited to determine the binding stoichiometry between PAI-1121-NBD with SMB–IDDΔ71 or SMB.
The concentration of PAI-1121-NBD was fixed at 50 nM, and
the concentration of the vitronectin fragments varied from
0 to 400 nM. The change in fluorescence intensity, (F − F0)/
(Fm − F0), was plotted against the concentration of SMB or
SMB–IDDΔ71 and fitted to Equation (3), which yielded a
1:1 binding stoichiometry between PAI-1 and SMB or SMB–
IDDΔ71 (Figure 3b), as observed previously with full-length
vitronectin titrations with PAI-1121-NBD.58
Stopped-flow fluorescence analyses were pursued to
monitor the presteady-state binding events between PAI1 and the vitronectin variants. Fluorescence spectra were
recorded up to 100 s after mixing of PAI-1121-NBD with
SMB, SMB–IDD, or SMB–IDDΔ71 (Figure 4). The
observed progress curves exhibit an initial rapid
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F I G U R E 5 Analyses of stopped-flow fluorescence progress curves demonstrate multiphase association kinetics with vitronectin
variants containing the IDD, but not with SMB alone. Shown are progress curves for the first 5 s of the reaction of PAI-1121-NBD (50 nM) with
SMB (200 nM): (a); with SMB–IDDΔ71 (200 nM): (b); or with SMB–IDD (200 nM): (c). Residual plots for mono- or bi-exponential models
are illustrated below the individual progress curves in each panel. IDD, intrinsically disordered domain; PAI-1, plasminogen activator
inhibitor type-1; SMB, somatomedin B

enhancement of fluorescence followed by a slow decay of
the signal. This slow fluorescence decay that is observed
in the experiment is similar to that observed with fulllength vitronectin, and has been attributed to PAI-1 conformational changes that occur over many seconds after
the initial binding events.58 Consistent with the fluorescence measurements made under steady-state conditions,
PAI-1121-NBD mixing with SMB–IDD or SMB–IDDΔ71
exhibits almost identical progress curves, while PAI1121-NBD mixed with the isolated SMB domain only
exhibits about 50% of the fluorescence enhancement relative to the results with mixing of PAI-1121-NBD with SMB–
IDD or SMB–IDDΔ71. The greater fluorescence enhancement that occurs upon PAI-1 mixing with SMB–IDD or
SMB–IDDΔ71 is consistent with the hypothesis that additional binding events occur beyond association with the
SMB domain.

To better characterize the initial binding events that
lead to the rapid fluorescence increase, the first 5 s of the
stopped-flow traces were used to extract kinetic parameters
(Figure 5). Data showing the initial changes in fluorescence
upon PAI-1121-NBD binding to isolated SMB, SMB–IDDΔ71,
and SMB-IDD are shown in Figure 5a–c, respectively. Mathematical fits of the data to one and two exponentials reveal
that the binding of SMB–IDD and SMB–IDDΔ71 to PAI-1 is
biphasic. This is best observed from the residuals for singleand double-exponential fits shown in the panels below each
trace. However, binding of PAI-1121-NBD to SMB alone fits
well to a monophasic curve, with both the single-phase and
two-phase fits yielding indistinguishable differences in the
residuals of the fits. These results indicate that there are two
rapid association events that occur upon interaction of PAI1 with SMB–IDD or SMB–IDDΔ71, while only one association event occurs with the isolated SMB domain.
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T A B L E 1 Association rates of PAI-1121-NBD binding with SMB,
SMB–IDD, or SMB–IDDΔ71
Kassoc-1 (M−1 s−1) Kassoc-2 (M−1 s−1)
PAI-1 + SMB

(1.74 ± 0.13) × 107

PAI-1 + SMB–IDD

(3.79 ± 0.29) × 107 (2.80 ± 1.00) × 106

PAI-1 + SMB–IDDΔ71 (4.18 ± 0.26) × 107 (4.22 ± 1.49) × 106
Abbreviations: IDD, intrinsically disordered domain; SMB, somatomedin B.

F I G U R E 6 Dependence of the observed association rates on
the concentration of the truncated forms of vitronectin. Reactions
were monitored over the first 5 s of the reaction to determine the
association rates constants of PAI-1121-NBD mixing with vitronectin
variants. The concentration of PAI-1121-NBD varied from 0.625 to
200 nM and the concentration of vitronectin proteins were kept at
fourfold molar excess of PAI-1121-NBD. Fits to the curves were
biphasic for SMB–IDD and SMB–IDDΔ71, yielding observed rate
constants for a fast and slow phase. Fits for binding of PAI-1121-NBD
to the isolated SMB domain were single-exponential fits yielding
one rate constant. Fast phase of PAI-1121-NBD mixing with SMB–
IDDΔ71: gray solid trace and closed circles; fast phase of PAI1121-NBD mixing with SMB–IDD: black solid trace and closed circles;
PAI-1121-NBD mixing with SMB: black solid trace and open squares;
slow phase of PAI-1121-NBD mixing with SMB–IDDΔ71: gray dashed
trace and open circles; slow phase of PAI-1121-NBD mixing with SMB–
IDD: black dashed trace and open circles. IDD, intrinsically
disordered domain; PAI-1, plasminogen activator inhibitor type-1;
SMB, somatomedin B

The variation in the observed rate constants for all of
the binding pairs was measured over a wide range in concentration by varying PAI-1121-NBD from 0.625 to 200 nM
and keeping the vitronectin species in at least a fourfold
molar excess of PAI-1121-NBD to maintain the pseudo-firstorder conditions (Figure 6). The observed association rates
increase linearly with the concentration of the vitronectin
variants. Association rate constants are derived from the
slopes and are listed in Table 1. The two association rate
constants for the binding of PAI-1121-NBD to SMB–IDDΔ71
were determined as kassoc-1 of (4.18 ± 0.26) × 107 M−1 s−1
and kassoc-2 of (4.22 ± 1.49) × 106 M−1 s−1. Similar values
were observed for binding of PAI-1121-NBD to SMB–IDD.
The association constant for the first binding event
described by kassoc-1 is comparable with the single association rate obtained for PAI-1121-NBD binding to SMB of (1.74
± 0.13) × 107 M−1 s−1 and is about 10-fold faster than the
second binding event described by kassoc-2. Thus, when
PAI-1 is mixed with SMB–IDD or SMB–IDDΔ71, these
results indicate that there is a high-affinity fast binding

event with the SMB domain and a lower affinity, slower
binding event that follows with the more extensive site outside of the SMB domain. These results are consistent with
the observation of biphasic binding with full-length
vitronectin and monophasic binding to the SMB domain
that was measured previously.58

3 | DISCUSSION
Early in the 21st century, the startling observation was
made that IDDs in proteins are quite abundant, with estimates indicating that up to two-thirds of eukaryotic proteins contain intrinsically disordered regions.75 When we
first identified the linker region joining the SMB domain
and the central domain of vitronectin, we noted that our
computational modeling predicted a lack of secondary
structure.49 At that time, our model for PAI-1:vitronectin
binding was restricted to the SMB domain, and we were
just beginning to recognize the complicated scenario that
has since emerged, with multiphase binding events and
conformational changes,58 assembly to higher-order PAI1:vitronectin structures,59,76 and an unusual assembly
intermediate with two molecules of vitronectin and four
molecules of PAI-1.76 We are now intrigued that the
linker domain appears to be intrinsically disordered,77,78
with low sequence complexity and amino acid compositional bias that plagued our initial structural modeling
attempts. Intrinsically disordered regions typically contain few bulky hydrophobic amino acids (Val, Leu, Ile,
Met, Phe, Trp, and Tyr), and a higher representation of
particular polar and charged amino acids (Gln, Ser, Pro,
Glu, Lys) and, on occasion, Gly and Ala.79,80 In many
cases, intrinsically disordered proteins or domains have
interesting functional properties81,82 and adopt specific
secondary structures and three-dimensional conformations based on folding/binding events that occur when
they interact with partner proteins/ligands.83
Recognizing that the intrinsically disordered character of the linker region in vitronectin could lend it structural adaptability for binding, we aimed to determine if
this region could account for the interesting biphasic
binding kinetics observed between vitronectin and PAI-1.
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Clearly, the SMB domain alone does not provide the full
interaction surface for PAI-1. We were guided by biochemical studies that mapped a more extensive binding
site in PAI-1 that extended beyond the flexible-joint
region known to bind the SMB domain.62 A highly
charged surface on PAI-1 was identified and shown to
interact with an engineered form of vitronectin lacking
the SMB domain.61 Recent studies with the isolated
SMB–IDD fragment from vitronectin demonstrated the
adoption of structure within the IDD upon binding to
PAI-1.57 These previous results laid the groundwork and
provided the rationale for this study. Our goals here were
to determine whether the SMB and IDD regions account
for the biphasic binding interactions, and, if so, to localize the PAI-1-binding site within the IDD.

3.1 | A PAI-1-binding site is located
within the portion of the IDD proximal to
the SMB domain
Taken together, the experiments testing the engineered SMB–
IDD and SMB–IDDΔ71 forms of vitronectin demonstrate that
a PAI-1-binding site is located within the first 24 amino acids
in the IDD: VFTMPEDEYTVYDDGEEKNNATVH. Two
PAI-1 variants, PAI-1(-4W) + F116W (containing an intrinsic fluorophore) and PAI-1121-NBD (containing an extrinsic
fluorophore), exhibit similar fluorescence changes upon
binding to SMB–IDD or SMB–IDDΔ71. The fluorescence changes observed upon PAI-1121-NBD binding to
the two truncated forms of vitronectin are essentially
equivalent to previous results with PAI-1121-NBD binding
to full-length vitronectin.58 In contrast, the binding of
either fluorescent form of PAI-1 with the isolated SMB
domain yields little change in fluorescence. The differences in fluorescence measured upon PAI-1 binding to
SMB–IDD or SMB–IDDΔ71 versus SMB show that there
is a direct PAI-1-binding site that is external to the wellcharacterized SMB region of vitronectin and is localized
within the IDD.
Rapid-reaction kinetics were studied using stoppedflow fluorescence analyses of PAI-1121-NBD binding to the
various forms of vitronectin. Previous stopped-flow fluorescence studies of PAI-1121-NBD mixing with full-length
vitronectin or SMB indicated that binding with
vitronectin is a two-step process, and only a single-step
event with SMB.58 The binding of PAI-1121-NBD with
SMB–IDD or SMB–IDDΔ71 exhibits two association
phases similar to what was previously measured with fulllength vitronectin. The fast phase, which has rates comparable to the rate of the binding of SMB alone, thus corresponds to the high-affinity binding of this N-terminal
domain from vitronectin to the flexible-joint region of
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PAI-1. The slower event, with a rate constant approximately 10-fold slower than the fast phase, is therefore
attributed to the lower-affinity binding of the more
extensive binding site identified on PAI-161 via residues
within the 48–71 sequence housed in the IDD region of
vitronectin.

3.2 | Models for the adoption of
structure within the IDD region upon PAI1 binding
Molecular dynamics was used to generate a structural model
of the PAI-1:SMB–IDDΔ71 complex to provide insight into
the adoption of structure within this 24-amino acid stretch
within the IDD, as well as to characterize potential binding
surfaces that interact with the charged region comprising
the more extensive vitronectin-binding site in PAI-1
(Figure 7). Four pairs of charge–charge interactions between
the acidic residues of SMB–IDDΔ71 and the basic residues
of PAI-1 were observed, including Arg120-Asp54*,
Arg78-Glu55*, Lys90-Glu64*, Lys147-Asp60* (residues
from SMB–IDDΔ71 are denoted with an Asterix).
Interestingly, the binding site within the IDD portion
of the SMB–IDDΔ71 fragment completely overlaps a site,
corresponding to amino acids 52–72 from vitronectin,
that we previously predicted as a sequence within the
IDD that could adopt structure.57 In the prior work, we
utilized the molecular recognition feature (MoRF) algorithm84 to make this determination. MoRFs are small segments in intrinsically disordered proteins that are predicted
to transition from disorder to order upon ligand binding.
This ordered state differs among MoRF sequences, and can
correspond to adoption of classic secondary structure or
an ordered loop region.85 The MoRF algorithm identified
two sequences within in the vitronectin linker region
that could undergo a coupled folding–binding process—
this sequence with residues 52–72, proximal to the SMB
domain, and a second more distal region encompassing
amino acids 84–95.57
Furthermore, our recent work using SANS demonstrated a gain of structure within the IDD upon binding
of the SMB–IDD fragment to PAI-1.57 These analyses
define a smaller conformational space available to the
IDD region within the PAI-1:SMB–IDD complex compared to the SMB–IDD structure alone. Monte Carlo
analysis and molecular dynamics approaches were used
to generate structural models for the PAI-1:SMB–IDD
complex that were compatible with the experimental
SANS data. From over 100,000 conformations, a small set
of structures were found to agree with the SANS data
collected across a series of solvent deuteration levels
in the contrast variation experiments. The two best-fit
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F I G U R E 7 Computational model of the PAI:SMB–IDDΔ71 complex. Left: Superimposition of the PAI:SMB–IDDΔ71 model with the
crystal structure of the PAI-1:SMB complex (PDB code: 1OC0). The structure of PAI-1:SMB is shown in a transparent silver rendering. In the
PAI:SMB–IDDΔ71 model PAI-1 is shown in magenta; SMB in red and the “VFTMPEDEYTVYDDGEEKNNATVH” peptide in orange. The
residues involved in the charge–charge interactions between the IDD and PAI-1 are shown with simple bond models (for residues of SMB–
IDDΔ71) or ball and stick models (for residues of PAI-1), respectively. Middle: 180 rotation relative to the image on the left. The PAI:SMB–
IDDΔ71 model is shown in a transparent rendering to better view the highlighted individual amino acids, and the PAI-1/SMB structure is
hidden. Right: Magnified view of the binding interface between the IDD and PAI-1. Residues within the SMB–IDDΔ71 are labeled with
Asterix to differentiate them from residues in PAI-1. All structures were generated in VMD. IDD, intrinsically disordered domain; PAI-1,
plasminogen activator inhibitor type-1; SMB, somatomedin B; VMD, Visual Molecular Graphics

structures demonstrate that the IDD residues that are
proximal to the SMB domain are in close contact with
the surface of PAI-1,57 consistent with the molecular
models of the PAI-1:SMB–IDDΔ71 complex shown in
Figure 7.

3.3 | Multiple events in the pathway of
assembly of PAI-1:vitronectin complexes
Due to the interesting reciprocal effects that PAI-1 and
vitronectin confer on the conformation, oligomeric state,
activity, and tissue localization of both proteins, we have
been eager to define the binding interfaces that promote
these changes. This work, combined with several studies
over the years, has established that assembly of PAI-1:
vitronectin complexes relies on multiple binding sites and
conformational changes that yield higher-order complexes.36,58,59,61,76 This work with PAI-1121-NBD binding to
the two truncated forms of vitronectin has pinpointed the
SMB domain and amino acids 48–71 in the IDD to
account for the interaction of vitronectin with PAI-1 in
two rapid binding events. It is important to note that the
structures of both PAI-1 and vitronectin change when they
interact, and these changes occur on a slower time scale
than the initial binding phases.58 These conformational

changes affect function, whereby the rates of reaction in
the attack of target proteases differ comparing free PAI-1,
the PAI-1:SMB complex, and the PAI-1:vitronectin complex.58 Furthermore, the conformational changes incurred
in vitronectin upon PAI-1 binding are proposed to lead to
assembly of the altered, multimeric form of vitronectin.
We have previously used analytical ultracentrifugation
to study the assembly of the multimeric PAI-1:vitronectin
complexes.76 These studies demonstrated a multistep mechanism for assembly of these complexes in a concentrationdependent fashion. While the contacts identified between
the flexible-joint region and the SMB domain are not ionic
in nature46 and high salt does not disrupt initial PAI-1 binding to vitronectin,59 we have determined that high ionic
strength indeed hampers formation of multimeric PAI-1:
vitronectin complexes.62 This salt dependency points to the
contribution of binding that depends on charge–charge
interactions to promote assembly of higher-order species.
Our results with SMB–IDDΔ71 that localize a binding site
within the highly charged 24-amino acid segment and provide structure models that define four key charge–charge
interactions. Further mutagenesis and/or structural studies
can be pursued to dissect the role of the individual ionic
bonding pairs in this mechanism.
Through identifying this site within the IDD, this
work on SMB–IDDΔ71 suggests that the binding between
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the IDD region and more extensive site on PAI-1 is a key
step in assembly of the higher-order PAI-1:vitronectin
complexes. This study and our recent SANS experiments57 underscore a unifying model for vitronectin
binding to PAI-1:(a) initial rapid binding of vitronectin to
PAI-1 in a biphasic reaction via the SMB and IDD regions
(timescale of milliseconds); (b) slower conformational
changes in both PAI-1 and vitronectin that promote a 2:1
complex (timescale of seconds); (c) assembly of higherorder PAI-1:vitronectin complexes (timescale of minutes);
(d) release of PAI-1 from the complexes on a slow time
scale characterized by conversion of PAI-1 to a latent,
inactive species (timescale of hours). Thus, the structural
changes that occur in the rapid folding–binding reaction
in the IDD region are proposed to transduce structural
changes throughout vitronectin, leading to the higherorder multimers that associate with tissues and mediate
cell-binding and signal transduction.

4 | EXPERIMENTAL PROCEDURES
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electrophoresis (SDS-PAGE) followed by western blotting
and matrix-assisted laser desorption/ionization time of
flight mass spectrometry (MALDI-TOF-MS) to confirm the
identity and purity of the protein.

4.2 | Fluorescence labeling of PAI-1
S121C
PAI-1 S121C was labeled with IANBD amide to create the
fluorescently labeled variant, PAI-1121-NBD as described
previously.58 DTT was first removed from purified PAI-1
S121C by passing the protein stock through an equilibrated PD-10 column (GE Healthcare) and eluting in
phosphate buffer (0.05 M NaH2PO4, 0.3 M NaCl, 1 mM
EDTA, pH 6.6) at 4 C by gravity flow. A 20-fold molar
excess of IANBD amide (in dimethylsulfoxide) was added
and the mixture was incubated in the dark overnight at
4 C. After incubation, free IANBD was removed by passing the mixture through a second PD-10 column. The
degree of IANBD labeling was calculated using the following equation:

4.1 | PAI-1 expression and purification
The amino acid residues in PAI-1 are referenced by the
numbering system of Andreasen et al.,86 starting at Ser1-Ala-2-Val-3-His-4-His-5. Wild-type (wt) PAI-1 and variants were expressed and purified as described before.87
Recombinant forms of human PAI-1 cloned in pET-24d
vector were expressed in Rosetta2 (DE3) pLysS cells for
growth and expression. The Agilent QuikChange SiteDirected Mutagenesis protocol was used to create mutations in PAI-1 at two sites (residues 116 and 121) in close
proximity to the proposed more extensive binding site of
PAI-1 that recognizes vitronectin residues outside of the
SMB domain (Figure 1). A form of PAI-1 lacking tryptophan (PAI-1(-4W)) was created by site-directed mutagenesis, introducing mutations at all four tryptophan codons in
wtPAI-1 and converting each to a phenylalanine codon.
Subsequently, we utilized the PAI-1(-4W) mutant and
introduced an F ! W replacement at position116 to generate a variant of PAI-1 that contains only a single tryptophan, denoted PAI-1(-4W) + F116W. PAI-1 S121C mutant
was created by replacing Ser-121 to Cys in wtPAI-1, as previously described.58 All mutations were confirmed by
DNA sequencing of the full-length PAI-1 gene. Wild-type
and mutant forms of PAI-1 were purified by using ion
exchange on SP-Sepharose, immobilized metal affinity
chromatography (IMAC) on nickel-charged resin, and gel
filtration on Sephacryl S-100 resin. 1,4-Dithiothreitol
(DTT) was added to all the buffers for PAI-1 S121C preparation to prevent dimerization. Purified proteins were subjected to sodium dodecyl sulfate polyacrylamide gel

AIANBD
MW of PAI− 1
×
εIANBD mg PAI − 1 ml − 1

ð1Þ

where the AIANBD is the absorbance of IANBD at its absorbance maximum wavelength 492 nm; εIANBD is the extinction coefficient for IANBD (25,000 M−1 cm−1); MW
(molecular weight of recombinant PAI-1 is 43,000 g mol−1);
the amount of PAI-1 is calculated as A280/εPAI-1, with an
εPAI-1 of 0.93 M−1 cm−1. The IANBD labeling efficiency for
PAI-1 in this study was above 0.9.

4.3 | Preparation of recombinant SMB,
SMB–IDD, and SMB–IDDΔ71
The SMB domain, corresponding to the sequence
encoding the first 47 amino acids of vitronectin (the
44 amino acid SMB region and RGD integrin-binding
sequence comprising residues 45–47) was cloned into the
pET-32b plasmid previously.60 The SMB–IDD fragment,
encompassing the first 130 amino acids of vitronectin,
was also produced in the pET-32B plasmid in prior
work.57 The SMB–IDDΔ71 fragment, which spans the
first 71 amino acids (the SMB domain and the following
“VFTMPEDEYTVYDDGEEKNNATVH” sequence) of
vitronectin, was generated by site-directed mutagenesis
using the QuikChange Site-Directed Mutagenesis protocol (Agilent) to introduce a new stop codon within the
coding sequence for the SMB–IDD. The resulting recombinant plasmids containing the vitronectin fragments
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were transformed into Rosetta gami 2(DE3) pLysS cells
for expression and purification as described previously.87
The cell lysate was first loaded on a nickel-charged IMAC
column, and proteins were eluted with a 20–1,000 mM
imidazole gradient. The eluted fraction containing the
vitronectin fragments fused to thioredoxin was treated
with thrombin to remove the fusion tags. After protease
cleavage, the protein mixture was loaded onto a second
nickel-charged IMAC column to remove the tags, which
bound to the column. The flow-through from the IMAC
column was collected and loaded onto a W175F PAI-1
affinity column to select the correctly folded vitronectin,
as previously described.60 SDS-PAGE, western blot and
MALDI-TOF-MS were used to confirm the identity and
purity at each step in the protein purification.

4.4 | PAI-1 activity assay
Plasminogen activator inhibitor Type-1 (PAI-1) activity was
measured by its ability to inhibit tPA using a chromogenic
assay as previously described.87 Various amounts of PAI-1
were mixed with 100 nM two-chain tPA (molar ratio of
PAI-1:tPA ranging from 0.2 to 4) and incubated for 30 min
in assay buffer (50 mM Tris, 100 mM NaCl, 0.01% Tween
20, 0.1% BSA, pH 7.4) at room temperature. The residual
activity of tPA in the PAI-1/tPA mixture was determined by
adding the substrate Spectrozyme tPA (final concentration
of 1 mM) and measuring the released p-nitroaniline at
405 nm for 20 min in a 96-well plate using a BioTek SYNERGY 4 microplate reader. Purified wtPAI-1 and PAI1121-NBD showed complete inhibition of tPA function at
about 1.25 equivalents. PAI-1(-4W) + F116W completely
inhibits tPA at about two equivalents.
A gel assay utilizing reduced SDS-PAGE was also performed as previously described60 to measure complexed,
cleaved, or uncleaved/latent PAI-1 upon mixing with tPA.
Single-chain tPA (Molecular Innovations; final concentration of 4 μM) was titrated with varying amounts of PAI-1
(molar ratio of PAI-1:tPA ranging from 0.5 to 3) in assay
buffer (50 mM Tris, 100 mM NaCl, 0.01% Tween
20, pH 7.4) for 10 min at room temperature. The sample
was then denatured and analyzed by SDS-PAGE. Gel
images were captured using a ChemiDoc XRS molecular
imager (Bio-Rad), and gel bands corresponding to different
forms of PAI-1 (complexed, uncleaved/latent, and cleaved)
were quantified using the Bio-Rad Image Lab software.
The band intensity of the uncleaved/latent PAI-1 was compared with that of total PAI-1 to estimate the activity of
PAI-1. All purified PAI-1 samples exhibited >85% activity.
The gel activity assay indicated that more PAI-1(-4W)
+ F116W was cleaved by tPA compared with wtPAI-1,
consistent with the fact that two equivalents of PAI-1
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(-4W) + F116W were needed to completely inhibit tPA in
the chromogenic activity assay.

4.5 | PAI-1 stability assay
The rate of PAI-1 latency conversion was measured by an
adaptation of a previous method.87 PAI-1 (25 nM) in the
absence or presence of SMB, SMB–IDD, or SMB–IDDΔ71
was incubated in assay buffer (50 mM Tris, 100 mM NaCl,
0.01% Tween 20, 0.1% BSA, pH 7.4) at 37 C. At various
time points, an aliquot of PAI-1 was removed and mixed
with 25 nM tPA. Initial rates were measured by adding
excess Spectrozyme tPA (Sekisui Diagnostics) to the reactions and monitoring the absorbance of p-nitroaniline at
405 nm for 5 min in a 96-well plate using a BioTek SYNERGY 4 microplate reader. The reaction slope was plotted
against PAI-1 incubation time to calculate tPA activity. A
normalized activity of PAI-1 was then determined by taking the negative slope and defining 100% activity at t = 0
time point and 0% activity at the longest time point, at
which PAI-1 was completely latent. The normalized PAI-1
activity at various time points was then fit to a one-phase
exponential decay model using the GraphPad Prism software to determine the half-life of PAI-1. Each measurement was conducted in triplicate, and an incubation time
of over 10 half-lives was covered. Under these experimental conditions, PAI-1 alone exhibits a half-life of ~100 min
and the complex of PAI-1 with SMB, SMB–IDD, or SMB–
IDDΔ71 exhibits a half-life of ~170–180 min.

4.6 | Steady-state fluorescence emission
spectroscopy
Fluorescence emission spectra of PAI-1(-4W) + F116W or
PAI-1121-NBD in the absence or presence of the individual
vitronectin variants were recorded at room temperature
using a Perkin Elmer LS51B luminescence spectrometer.
The excitation wavelength for the tryptophan fluorescence
in PAI-1(-4W) + F116W was 295 nm, and the emission
spectrum was collected from 300 to 500 nm. For measurements with PAI-1121-NBD, the excitation wavelength was
480 nm and the emission spectrum was recorded from
500 to 650 nm. For the fluorescence titration measurements, 50 nM of PAI-1121-NBD was mixed with various
amounts of the SMB or SMB–IDDΔ71 vitronectin variants
(ranging from 0.625 to 800 nM) in the assay buffer
(50 mM Tris-Cl, 150 mM NaCl, pH 7.6 at 22 C). Using an
excitation wavelength of 480 nM, fluorescence intensity at
530 nm was monitored and then normalized using the following equation to monitor the fraction changes upon
binding of various forms of vitronectin:
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F − F0
F m −F 0

ð2Þ

where F0 is the fluorescence intensity of PAI-1121-NBD in the
absence of vitronectins and Fm is the maximal fluorescence
intensity of PAI-1121-NBD in the titration measurements with
the vitronectin variants added. The normalized intensity
was plotted against the concentration of added SMB or
SMB–IDDΔ71. Each experiment was performed in triplicate. Binding constants were estimated by a nonlinear least
square fit to the following equation:

F −F 0
=
Fm − F0

R + T + K − ðR + T + K Þ2 − 4TR

12 

2R

ð3Þ

in which R is the total concentration of the vitronectin
variant, T is the total concentration of PAI-1121-NBD, and
K is the dissociation constant for PAI-1121-NBD:vitronectin
interactions.

4.7 | Fluorescence stopped-flow analysis
of PAI-1:vitronectin binding
Stopped-flow fluorescence measurements of PAI-1121-NBD
binding to the vitronectin truncation variants were performed on an Applied Photophysics SX20 Stopped Flow
Spectrometer at 20 C. For each reaction, PAI-1121-NBD
(from 6.25 to 200 nM) was mixed with a fourfold molar
excess of SMB, SMB–IDD, or SMB–IDDΔ71 in assay
buffer (50 mM Tris-Cl, 150 mM NaCl, pH 7.6 at 22 C).
The excitation wavelength was 480 nm, and a cut-off filter
of 530 nm was used to collect the emitted fluorescence. An
experiment mixing PAI-1121-NBD with buffer only was
recorded as a baseline and subtracted from all experiments
in which PAI-1121-NBD was mixed with the various
vitronectin forms. The stopped-flow fluorescence recorded
within the rapid increase phase (first 5 s) of PAI-1121-NBD
mixing with the various truncated forms of vitronectin
was fit to one-phase or two-phase association using the
GraphPad Prism software to obtain pseudo-first-order rate
constants kobs-1 and kobs-2. The obtained kobs values were
plotted against the concentration of the various truncated
vitronectin variants to determine the slope, which represents the rate constants kassoc-1 or kassoc-2.

4.8 | Molecular dynamics modeling of
the complex of PAI-1 and SMB–IDDΔ71
The “VFTMPEDEYTVYDDGEEKNNATVH” sequence following the SMB domain was docked into PAI-1:SMB

complex (PDB ID:1OC046) using CABS-dock.88,89 Ten
models were generated, and the model with the peptide
docked in the extensive binding pocket of PAI-1 was
selected. The docked peptide was then linked to the SMB
domain to get the initial PAI-1:SMB–IDDΔ71 complex
structure. The initial system was minimized, solvated, minimized again, equilibrated, and simulated in the NAMD program90 using the CHARMM36 force field91 to obtain the
final model. A periodic boundary condition was used. The
particle mesh Ewald92 algorithm was used to treat longrange electrostatic interactions, and the SHAKE algorithm93
was applied to constrain bonds involving hydrogen atoms.
Nonbonding interactions were truncated at 12.0 Å. The initial structure was first minimized and then solvated by placing a water box with dimensions of 10 Å in each direction
from the atom with the largest coordinate in that direction.
The solvated system was subjected to another energy minimization and heating to a temperature of 310 K, followed
by 0.5 ns of equilibration. About 5.0 ns of molecular
dynamics simulation was performed to obtain the final
PAI-1:SMB–IDDΔ71 model. All of the simulations were
performed at a constant temperature of 310 K and a constant pressure of 1 atm. The simulation time step was 2 fs.
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